BREATH TEST FOR LUNG CANCER

肺癌呼吸测试

• 批准号: 2604735
• 负责人: MICHAEL CANAVAN PHILLIPS
• 金额: $ 10万
• 依托单位: MENSSANA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1999-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2604735
• 关键词: alkanes; biomarker; breath tests; bronchoscopy; clinical research; diagnosis design /evaluation; diagnosis quality /standard; early diagnosis; free radical oxygen; gas chromatography mass spectrometry; human subject; lung neoplasms; methylation; neoplasm /cancer diagnosis; noninvasive diagnosis; smoking

Carcinogenesis is accompanied by increased production of oxygen free radicals (OFRs). OFRs degrade membranes by lipid peroxidation, releasing volatile organic compounds (VOCs) which are excreted in the breath. Hence, breath VOC analysis may detect biomarkers of cancer. Breath VOCs were analyzed in 108 patients with abnormal chest x-rays. 60 were found to have lung cancer at bronchoscopy. 36 VOCs, predominantly methylated alkanes, were significantly different in the lung cancer patients. A discriminant analysis model (with 20 VOCs) was 90% sensitive and 87.5% specific for lung cancer. Hypothesis: Breath VOC analysis may provide a clinically useful new test for early diagnosis of lung cancer. Experimental plan to test the hypothesis: 1. Breath VOCs will be analyzed in 200 patients undergoing bronchoscopy because of an abnormal chest x-ray suggestive of lung cancer. 2. The probability of lung cancer will be predicted from the breath test. 3. Breath test predictions will be compared to the biopsy diagnosis, and the sensitivity, specificity, and predictive value of the breath test will be determined. The long-term aim of the research is to determine the diagnostic value of breath testing as a tool for the early detection of lung cancer in mass screening surveys. Proposed commercial applications: Breath testing could provide a non-invasive diagnostic tool for the early detection of lung cancer in mass screening surveys.

致癌作用伴随着游离氧的产生增加 自由基（OFR）。OFR通过脂质过氧化降解膜，释放 挥发性有机化合物（VOC），在呼吸中排出。因此，我们认为， 呼吸VOC分析可以检测癌症的生物标志物。呼吸VOC为 分析了108例胸部X线检查异常的患者。60人被发现 支气管镜检查发现肺癌。36种挥发性有机化合物，主要是甲基化烷烃， 在肺癌患者中有显著性差异。判别 分析模型（含20种VOCs）的灵敏度为90%，特异性为87.5%， 肺癌假设：呼吸VOC分析可以提供临床 肺癌早期诊断的新方法实验计划， 测试假设：1。将在200名患者中分析呼吸VOC 因为异常胸部X光检查提示 肺癌2.肺癌的发病率将从 呼吸测试3.呼吸测试预测将与活检进行比较 诊断，以及敏感性，特异性和预测价值， 呼吸测试将被确定。研究的长期目标是 确定呼吸测试作为早期诊断工具的诊断价值 在大规模筛查调查中发现肺癌。 拟议的商业应用： 呼吸测试可以提供一种非侵入性的诊断工具， 在大规模筛查调查中发现肺癌。